Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris N.V. (NASDAQ:PHVS) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 636,914 shares, a growth of 43.7% from the November 30th total of 443,097 shares. Based on an average daily trading volume, of 653,889 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.2% of the shares of the stock are short sold. Approximately 1.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 653,889 shares, the days-to-cover ratio is presently 1.0 days.

Pharvaris Price Performance

Shares of PHVS stock traded down $0.02 during trading hours on Monday, hitting $25.74. The company had a trading volume of 122,073 shares, compared to its average volume of 156,984. The stock has a market capitalization of $1.35 billion, a PE ratio of -8.02 and a beta of -2.80. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $29.80. The company’s fifty day moving average is $24.47 and its 200 day moving average is $22.53.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.08. Equities analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of recent research reports. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Wedbush upped their price target on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. Morgan Stanley upped their target price on Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Finally, Oppenheimer lifted their price target on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palumbo Wealth Management LLC grew its position in shares of Pharvaris by 3.2% in the 2nd quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after buying an additional 447 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. HighVista Strategies LLC boosted its position in shares of Pharvaris by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after purchasing an additional 971 shares during the period. California State Teachers Retirement System grew its stake in Pharvaris by 9.8% during the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after buying an additional 1,257 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.